Use

Nowcasting consumer price inflation using high-frequency scanner data: evidence from Germany

Retrieved on: 
Tuesday, April 23, 2024
Consensus, Online, Cream, Honey, Tax, Glass, MAPI, Consensus Economics, Journal of Economic Perspectives, Milk, Shower, Low-alcohol beer, Autoregressive–moving-average model, Infant, C3, Islam, Wine, Core inflation, Research Papers in Economics, National accounts, Kálmán, Barcode, Journal of International Economics, Communication, Royal Statistical Society, COVID19, Kohl (cosmetics), Natural disaster, Business, Observation, Paper, VAT, European Economic Review, Diebold Nixdorf, Blancmange, Calendar, Sunflower oil, Annual Review of Economics, Hand, C4, DESTATIS, NBER, Tinning, Razor, Forecasting, Gasoline, Coffee, European Economic Association, Cat, Journal of Monetary Economics, Journal of Applied Econometrics, Medeiros, Architecture, Oxford University Press, Producer, GfK, Quarterly Journal of Economics, Margarine, NCBS, Starch, Political economy, Consistency, COVID-19, Consensus decision-making, Website, MIDAS, Behavior, Deutsche Bundesbank, PPI, World Bank, Collection, Medical classification, Orange, Eurozone, Butter, FMCG, Noise, Travel, Clothing, History, Inflation, Liver, International economics, Journal of Political Economy, BSI, OLS, Statistics, Consumer, PDF, University of Chicago, Classification, ECB, Fats, Policy, Multi, WOB, Outline, C6, Mincing, Canadian International Council, Social science, Perfume, University of California, Berkeley, Journal of Forecasting, Federal Reserve Bank, JEL, L1, Journal, Research, Candle, Food, TPD, Credit, Spice, LPG, Janssen, Marmalade, Superior, Literature, Chocolate, Beef, Kiel University, European Central Bank, Natural gas, HICP, Monetary economics, Yogurt, Section 5, ILO, Bermingham, Price, GTIN, Cheese, Macroeconomics, Growth, Beck, XJ, Government, De Beer, Supermarket, Ice cream, Naturally, C53, Corn flakes, BIS, Biscuit, LASSO, Petroleum, A.2, Poultry, Accuracy and precision, Application, White, Lettuce, Risk, ESCB, University of Siegen, OECD, Chapter One, Lipstick, Sack, XT, BIC, Garlic, Consumption, Sokol, Meat, VAR, Database, Section 3, Rusk, American Economic Journal, Royal, Curd, Overalls, Lamb, Great Lockdown, Fruit, Economy, COICOP, International Journal of Forecasting, Aftershave, Section 2, Nonparametric statistics, Attention, Conference, CPI, Heat, Public economics, Common sunflower, Nowcasting, American Economic Review, Computational Statistics (journal), GFK, COVID-19 pandemic, Exercise, Shock, Running, UNECE, Edible, Gambling, Banco, Rigid transformation, European Commission, Frozen, C.2, PRISMA, Official statistics, Concept, Drink, Transaction data, Somatosensory system, Punctuality, Altbier, Food prices, Response, GDP, Index, E31, Cabinet of Germany, Holiday, Machine learning, Series, Green, Whisky, Vegetable, Cola, Journal of Econometrics, Sadik Harchaoui, University, Aggregate, World Bank Group, B.1, Use, Book, Economic statistics, Civil service commission, 1L, Apple, Bread, Filter, Central bank, Brandeis University, Economic Modelling, Bank, Barkan, Roulade, Dairy product, Neural network, Reproduction, IMF, Section, ID, Data, D4L, Cryptocurrency
Key Points: 

    FPF Submits Comments to the Office of Management and Budget on AI and Privacy Impact Assessments

    Retrieved on: 
    Thursday, April 18, 2024
    FPF, Organization, Future of Privacy Forum, Federation, Society, Trust (social science), Management, AI, Privacy, PIAS, Risk assessment, OMB, Comment, Automation, Public sector, Use, RFI, Artificial intelligence, PIA, Medical device

    FPF Submits Comments to the Office of Management and Budget on AI and Privacy Impact Assessments

    Key Points: 
    • FPF Submits Comments to the Office of Management and Budget on AI and Privacy Impact Assessments
      On April 1, 2024, the Future of Privacy Forum filed comments to the Office of Management and Budget (OMB) in response to the agency’s Request for Information on how privacy impact assessments (PIAs) may mitigate privacy risks exacerbated by AI and other advances in technology.
    • As privacy impact assessments are a well-established means for both public and private entities to assess privacy risks in their services, products, and programs, there is a tremendous opportunity for federal agencies to apply learnings from existing data privacy to the challenges that AI presents as a rapidly evolving technology.
    • Ensuring that the scope and substance of a PIA for AI tools account for role-specific responsibilities and capabilities in the AI system lifecycle.
    • “Whether conducted by the public sector, private companies, or other entities, privacy impact assessments can play an important role in evaluating and mitigating certain risks associated with technology.

    iLobby Named a Leader in the 2024 Spring G2 Grid® for Visitor Management Software

    Retrieved on: 
    Monday, April 1, 2024
    Visitor management, Easy, Ease, Use, Administration

    TORONTO, April 01, 2024 (GLOBE NEWSWIRE) -- iLobby, the global leader in enterprise facility and visitor management solutions, today announced the company has been named a Leader in the Spring 2024 G2 Grid® for Visitor Management Software .

    Key Points: 
    • TORONTO, April 01, 2024 (GLOBE NEWSWIRE) -- iLobby, the global leader in enterprise facility and visitor management solutions, today announced the company has been named a Leader in the Spring 2024 G2 Grid® for Visitor Management Software .
    • iLobby continues to solidify its position as a competitive player in the visitor management solutions market and is currently holding the top spot as the Easiest To Use in Visitor Management software .
    • “We thank our customers for their ongoing support and are proud to be named a Leader by G2 in their most recent Visitor Management Software Grid,” notes Ariel Mashiyev, CEO of iLobby.
    • “iLobby has been recognized in the past six Grid ® for Visitor Management reports as a Leader.

    The AI revolution is here: Samsung brings Galaxy AI to more smartphones

    Retrieved on: 
    Tuesday, March 26, 2024
    Translation, Suggestion, UI, Edit, Communication, Samsung Galaxy, Samsung Galaxy S23, PNG, RSS, Patch (computing), AI, Photography, Life, Ultimate, APR, Samsung, Samsung Galaxy Z series, Note, JPG, Human voice, Language, VZ, Use, Work, Android, MP4, Mobile phone

    This expansion includes popular models, such as the Galaxy S23 series, Galaxy S23 FE , Galaxy Z Fold5 and Galaxy Z Flip5 .

    Key Points: 
    • This expansion includes popular models, such as the Galaxy S23 series, Galaxy S23 FE , Galaxy Z Fold5 and Galaxy Z Flip5 .
    • Whether you’re upgrading to the Galaxy S23 series, Galaxy S23 FE , Galaxy Z Fold5 and Galaxy Z Flip5 , Verizon has the perfect plan to match your needs.
    • Availability: Samsung One UI 6.1 with Galaxy AI features will be provided at no charge to Verizon customers using the Galaxy S23 series, Galaxy S23 FE , Galaxy Z Fold5 and Galaxy Z Flip5 starting March 28.
    • Check out our feature video on Galaxy AI to learn more about this amazing new technology, and visit Verizon’s Samsung Galaxy page to find the Galaxy smartphone that’s perfect for you.

    HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

    Retrieved on: 
    Tuesday, March 26, 2024
    Diabetes, Disease, Echocardiography, HSCS, Congress, Algorithm, Intelligence, Anesthesia, Patient, Mortality, LVDD, Society, Anesthesiology, Type, Use, American Society of Echocardiography, Medical device

    Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.

    Key Points: 
    • Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.
    • In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled.
    • For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.
    • Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography.

    CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

    Retrieved on: 
    Saturday, April 6, 2024
    Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

    HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

    Key Points: 
    • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
    • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
    • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
    • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

    Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

    Retrieved on: 
    Monday, March 25, 2024
    Orphan drug, Primary sclerosing cholangitis, Inflammation, Fast Track, European Patent Organisation, Antibody, PSC, Liver, Liver transplantation, Doctor of Philosophy, CCL24, Fibrosis, Treatment, Therapy, European Patent Convention, CMMB, Patent, Use, Hepatology, FDA, TEL, Pharmaceutical industry

    TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today reported that the European Patent Office has granted a new patent for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.

    Key Points: 
    • CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC).
    • Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.
    • The new European patent covers the use of CM-101 and sequence-related anti-CCL24 antibodies for the treatment of hepatic (liver) diseases, including PSC.
    • Unlike other drugs in development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation.

    FDA Clears RedDrop Dx, Inc.’s Blood Collection Device, RedDrop One

    Retrieved on: 
    Friday, March 22, 2024
    Plasma, Patient, Phlebotomy, Clinical trial, CO, Use, Blood, FDA, Collection, Health, Food, Fort Collins, Colorado, Pharmaceutical industry

    Fort Collins, CO, March 22, 2024 (GLOBE NEWSWIRE) -- RedDrop Dx , Inc., Innosphere Ventures Client Company, is pleased to announce that its innovative blood collection device, RedDrop One, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for prescription use.

    Key Points: 
    • Fort Collins, CO, March 22, 2024 (GLOBE NEWSWIRE) -- RedDrop Dx , Inc., Innosphere Ventures Client Company, is pleased to announce that its innovative blood collection device, RedDrop One, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for prescription use.
    • This clearance marks a significant step forward for RedDrop Dx in enhancing blood collection technology and patient care practices.
    • RedDrop One offers several key advantages over traditional blood collection methods, including the ability to collect a larger volume of blood more easily, with increased reliability and reduced discomfort for the user.
    • The device is designed to meet the needs of both patients and healthcare providers by offering a more efficient and less painful blood collection experience.

    NextCure Provides Business Update and Reports Full Year 2023 Financial Results

    Retrieved on: 
    Thursday, March 21, 2024
    Research, Toxicity, Bone disease, Agreement, Osteogenesis imperfecta, DAR, AML, Risk, Patient, MMAE, Mouse, OI, Public expenditure, Plaque, Apolipoprotein E, PRS, IND, ARIA, GMP, Osteoporosis, CRC, Workforce, Use, ADC, Osteoarthritis, FDA, GLP, Pharmaceutical industry

    We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.

    Key Points: 
    • We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.
    • Selected our first antibody drug conjugate (ADC) candidate of a potential of three from our collaboration with LegoChem Biosciences, Inc. (LegoChem).
    • Under the terms of the Agreement, both parties equally share the costs of developing the molecules and profits on commercialized products.
    • Implemented a restructuring plan to reduce operating costs and better align our workforce with the needs of our business.

    Equinor presents 2023 Integrated annual report

    Retrieved on: 
    Thursday, March 21, 2024
    Annual report, Lindworm, Tax, Growth, Exchange, Snorre, Anders Opedal, GHG, Global warming potential, Gullfaks oil field, History, Acquisition, Security (finance), CCS, Nature, Carbon, Disclosure, Bank statement, Accident, Publication, CO2, Kilowatt-hour, Energy, ASA, Gina Krog, Use, Baugé, USD, NCS, Fatality, EQNR, Renewable energy

    Equinor ASA (OSE: EQNR, NYSE: EQNR) publishes 2023 Integrated annual report, combining financial and sustainability reporting.

    Key Points: 
    • Equinor ASA (OSE: EQNR, NYSE: EQNR) publishes 2023 Integrated annual report, combining financial and sustainability reporting.
    • The report for 2023 integrates the annual financial and sustainability reporting, reflecting the importance of sustainability for Equinor’s operational and financial performance, to our people, investors and other stakeholders.
    • The Equinor 2023 Annual Report on Form 20-F may be downloaded from Equinor's website at www.equinor.com.
    • See Use and reconciliation of non-GAAP financial measures in the integrated annual report for more details.